Remove Biopharma Remove Physicians Remove Prescription
article thumbnail

Veradigm® Digital Health Media Works to Message the Right Physicians at the Right Time

PM360

As pharma reps’ access to physicians continues to decline, this case study examines the effectiveness of reaching physicians through other means—the EHR. Today’s physicians struggle to balance the increasing demands of patient loads, electronic health record (EHR) systems, and time spent on administrative tasks. THE CHALLENGE.

article thumbnail

Powering pharma’s commercial teams with market access insights

pharmaphorum

Market access is influencing drug development and commercial launch strategy more than ever before, with 85% of prescription drugs in the United States reimbursed through managed care plans.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Bringing Therapies from Bench to Bedside: Navigating Challenges in the Last Mile

Clarify Health

There is also a looming, time-sensitive reality that biopharma companies face once their products hit the market: they need to recoup the costs of development as quickly as possible before drug patents expire and generics threaten sales. Which physicians see these patients? sales, medical science liaisons, etc.).

article thumbnail

Five ways COVID-19 has changed healthcare provision and what it means for pharmas

Clarivate

2021 surveys of patients and physicians in the United States conducted by Clarivate show that: Much of care delivery has gone virtual. Three in five physicians in the United States (60%) report having conducted virtual consultations, as do 35% of patients. physicians; Source: Clarivate, Taking the Pulse(R) U.S.

Pharma 52
article thumbnail

The AMJEVITA impact: Innovative U.S. biosimilar pricing models

Clarivate

biologics market and reduce prescription drug costs. and European physicians across six specialties, and global pipeline analysis curated by experts to provide insights into the evolving landscape. By end of year, as many as ten adalimumab biosimilars could be on the U.S. In 2022, it made its manufacturer, AbbVie, $21.2bn.

article thumbnail

Five points on CMS’s first ten picks for price negotiations

Clarivate

While more expensive than type 2 diabetes drugs, blood thinners follow a similar pattern of high prescription volumes. In both cases, a shift in formulary placement could lower prescription volumes and reduce member utilization. With 27.5% exclusions exist for orphan drug designation and biosimilar competition ).

article thumbnail

Leading speciality pharmacies in pharma

Pharmaceutical Technology

The speciality drug channel participants, including speciality pharmacies, biopharma companies, and distributors, are transforming their operations with automated and secure data systems and next-generation analytics, which will improve data collection, partner performance and strategy effectiveness. . Prescription refill and renewal.